更正：AMG-232使高表达MDM2的肿瘤细胞对T细胞介导的杀伤敏感。
Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.
作者信息
Sahin Ilyas, Zhang Shengliang, Navaraj Arunasalam, Zhou Lanlan, Dizon Don, Safran Howard, El-Deiry Wafik S
机构信息
Joint Program in Cancer Biology, Brown University and Lifespan Health System, Providence, RI USA.
Division of Hematology/Oncology, The Warren Alpert Medical School, Brown University, Providence, RI USA.
出版信息
Cell Death Discov. 2020 Aug 7;6:71. doi: 10.1038/s41420-020-00310-1. eCollection 2020.
Abstract
[This corrects the article DOI: 10.1038/s41420-020-0292-1.].
摘要
[本文更正了文章的数字对象标识符：10.1038/s41420-020-0292-1。]
相似文献
1
Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.更正：AMG-232使高表达MDM2的肿瘤细胞对T细胞介导的杀伤敏感。
Cell Death Discov. 2020 Aug 7;6:71. doi: 10.1038/s41420-020-00310-1. eCollection 2020.
2
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.AMG-232使高表达MDM2的肿瘤细胞对T细胞介导的杀伤敏感。
Cell Death Discov. 2020 Jul 6;6:57. doi: 10.1038/s41420-020-0292-1. eCollection 2020.
3
Erratum: Publisher Correction: articles initially published in wrong volume.勘误：出版商更正：文章最初发表于错误卷期。
Cell Death Discov. 2019 Jul 10;5:116. doi: 10.1038/s41420-019-0186-2. eCollection 2019.
4
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII.AMG 596的临床前评估，一种靶向肿瘤特异性抗原EGFRvIII的双特异性T细胞衔接器（BiTE）免疫疗法。
Mol Cancer Ther. 2021 May;20(5):925-933. doi: 10.1158/1535-7163.MCT-20-0508. Epub 2021 Feb 25.
5
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.MDM2 抑制剂 AMG 232 具有强大的抗肿瘤疗效，并增强了 p53 诱导细胞毒性药物的活性。
Mol Cancer Ther. 2015 Mar;14(3):649-58. doi: 10.1158/1535-7163.MCT-14-0710. Epub 2015 Jan 7.
6
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.在晚期 P53 野生型实体瘤或多发性骨髓瘤患者中进行 MDM2 抑制剂 AMG 232 的 I 期研究。
Invest New Drugs. 2020 Jun;38(3):831-843. doi: 10.1007/s10637-019-00840-1. Epub 2019 Jul 29.
7
Correction to: IRE1α deficiency promotes tumor cell death and eIF2α degradation through PERK-dependent autophagy.对《IRE1α 缺乏通过 PERK 依赖的自噬促进肿瘤细胞死亡和 eIF2α 降解》的修正
Cell Death Discov. 2018 Jul 26;4:19. doi: 10.1038/s41420-018-0082-1. eCollection 2018.
8
Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.靶向上皮细胞黏附分子（EpCAM）的标记双特异性T细胞衔接抗体的生物分布及正电子发射断层显像（PET）成像
J Nucl Med. 2016 May;57(5):812-7. doi: 10.2967/jnumed.115.168153. Epub 2016 Feb 4.
9
Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia.AMG 553 的非临床安全性评估，一种用于治疗急性髓系白血病的研究性嵌合抗原受体 T 细胞疗法。
Toxicol Sci. 2020 Sep 1;177(1):94-107. doi: 10.1093/toxsci/kfaa098.
10
Correction: Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma.更正：在动物模型中，全身给予peptain-1可抑制视网膜神经节细胞死亡：对青光眼神经保护的意义。
Cell Death Discov. 2019 Jul 31;5:122. doi: 10.1038/s41420-019-0201-7. eCollection 2019.
引用本文的文献
1
Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy.卵巢癌免疫治疗中的蛋白质泛素化：进展与治疗策略
Genes Dis. 2023 Oct 29;11(6):101158. doi: 10.1016/j.gendis.2023.101158. eCollection 2024 Nov.
2
The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer.免疫治疗增敏剂和新型免疫治疗模式在癌症治疗中的作用。
Front Oncol. 2024 Feb 27;14:1336546. doi: 10.3389/fonc.2024.1336546. eCollection 2024.
3
RUNX3 Meets the Ubiquitin-Proteasome System in Cancer.RUNX3 在癌症中遇见泛素-蛋白酶体系统。
Cells. 2023 Feb 24;12(5):717. doi: 10.3390/cells12050717.
4
AMG-232, a New Inhibitor of MDM-2, Enhance Doxorubicin Efficiency in Pre-B Acute Lymphoblastic Leukemia Cells.AMG-232，一种新型MDM-2抑制剂，可提高阿霉素在早前B细胞急性淋巴细胞白血病细胞中的疗效。
Rep Biochem Mol Biol. 2022 Apr;11(1):111-124. doi: 10.52547/rbmb.11.1.111.
Zotero 插件